Comparative Pharmacology
Head-to-head clinical analysis: GLUCOPHAGE versus GLUCOPHAGE XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUCOPHAGE versus GLUCOPHAGE XR.
GLUCOPHAGE vs GLUCOPHAGE XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin primarily decreases hepatic glucose production (gluconeogenesis) and increases peripheral insulin sensitivity, reducing glucose absorption from the gastrointestinal tract. It activates AMP-activated protein kinase (AMPK), leading to inhibition of gluconeogenic enzymes.
Biguanide; decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
500 mg orally once daily, titrate by 500 mg weekly; max 2000 mg/day divided twice daily; extended-release: 500 mg orally once daily, titrate by 500 mg weekly; max 2000 mg/day once daily.
Metformin XR: initial 500 mg orally once daily with evening meal, increase by 500 mg weekly; max 2000 mg per day (as XR, given once or divided twice daily).
None Documented
None Documented
Terminal elimination half-life: 6.2 hours (range 4.0-8.7 h); prolonged in renal impairment (up to 17.6 h at CrCl <60 mL/min).
Terminal elimination half-life: 17.6 hours (range 9.1–40.6 hours); clinical context: reflects slow absorption from extended-release matrix; accumulation occurs with renal impairment
Renal elimination of unchanged drug: 90%; fecal: 10% (biliary negligible).
Renal: 90% unchanged; fecal: minimal (<5%)
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic